Benzofuran compound and application thereof

Abstract

The invention discloses a benzofuran compound and application thereof. The benzofuran derivative disclosed by the invention is a compound with TRPM3 antagonistic activity, has an important potential treatment value, and is applied to medicines for treating neuropathic pain or migraine.

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of pharmacy, and relates to a kind of benzofuran derivatives and a preparation method thereof, application as TRPM3 antagonist, in particular, purposes in the drug for treating neuropathic pain or migraine. BACKGROUND

[0002] Pain, as a warning signal of the body to potential harm or disease, can be acute, such as transient discomfort after trauma, or chronic, lasting for weeks, months or even longer, affecting the daily function and mental health of patients. Neuropathic pain refers to severe pain caused by damage or dysfunction of the nervous system, and its symptoms may include persistent burning, tingling or electric shock-like pain, causing great physical and mental distress to patients. Migraine, as a special type of headache, is characterized by recurrent unilateral or bilateral pulsatile headache, often accompanied by nausea, vomiting, sensitivity to light and sound, and other symptoms, which seriously affects the work, study and social activities of patients. These diseases not only increase the medical burden of patients, but also may lead to long-term psychological problems such as anxiety and depression, further exacerbating the impact of the disease. Traditional treatment methods can relieve pain to some extent, but often have problems such as drug dependence and obvious side effects. Therefore, there is an urgent need for safe, effective and non-opioid therapeutic drugs to meet the huge demand.

[0003] TRPM3, as a member of the TRP channel family, is a non-selective cation channel with high permeability to calcium ions. It is widely expressed in nociceptive sensory neurons and plays a key role in the transmission of pain signals. Studies have shown that TRPM3 can be activated by various endogenous and exogenous ligands, and is involved in the occurrence of inflammatory and neuropathic pain. More importantly, TRPM3 antagonists have shown significant analgesic effect in animal models, not only effectively relieving thermal and mechanical pain, but also not adversely affecting body temperature, which is significantly different from traditional TRPV1 antagonists. Therefore, the development of TRPM3 target and its antagonists provides a new strategy for the treatment of pain, neuropathic pain and migraine, and is expected to become an important target for the next generation of analgesic drugs.

[0004] The present application relates to a class of compounds with TRPM3 antagonistic activity, which can be used for the treatment of neuropathic pain or migraine. SUMMARY

[0005] The technical problem solved by the present application is to provide a class of benzofuran derivative compounds, which have TRPM3 antagonistic activity and can be used for the preparation of drugs for treating neuropathic pain or migraine.

[0006] Technical solution: A class of compounds as shown in Formula I, or pharmaceutically acceptable salts, deuterated compounds, solvates, racemic mixtures, enantiomers, diastereomers, and tautomers thereof.

[0007]

[0008] Among them, W1, W2 and W3 are each independently selected from -C(R9)-, -N-, -N(R8)-, -O- or -S-; W4 is selected from -C(R9)-, -N- or W4 is the key;

[0009] L is selected from -C(R) 10 R 11 )-、-N(R 12 -, -S-, or -O-;

[0010] R1, R2, R3, R4, R5, R6, R7, and R9 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, and C. 1-14 Alkyl, C 3-14 cycloalkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 aryl or 5 to 14-membered heteroaryl, wherein the above groups are optionally further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted by aryl or 5 to 14 heteroaryl groups;

[0011] X is selected from -NR 13 R 14 ;

[0012] R 10 and R 11 Each is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 cycloalkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 aryl or 5 to 14-membered heteroaryl, or R 10 R 11 Together with the carbon atom directly attached to it, it forms a carbonyl group, C 3-14Cycloalkyl or 3 to 14-membered heterocyclic groups, wherein the above groups are optionally further surrounded by one or more groups selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted by aryl or 5 to 14 heteroaryl groups;

[0013] R8 and R 12 Each is independently selected from hydrogen, deuterium, hydroxyl, amino, C 1-14 Alkyl, C 3-14 cycloalkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 aryl or 5 to 14-membered heteroaryl, wherein the above groups are optionally further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted by aryl or 5 to 14 heteroaryl groups;

[0014] R 13 Selected from hydroxyl or R Y1 ;

[0015] R 14 Selected from R Y2 or -S(O)2R Y3 Or R 13 R 14 Together with the nitrogen atom directly bonded thereto, it forms a saturated or unsaturated 3- to 14-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, or S, wherein the 3- to 14-membered heterocycle is optionally further bounded by one or more atoms selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted by aryl or 5 to 14 heteroaryl groups;

[0016] R Y1 R Y2R Y3 Independently selected from each other in each case: hydrogen;

[0017] Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted C 1-6 alkyl;

[0018] Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted C 1-6 Heteroalkyl;

[0019] Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl groups; wherein the 3- to 14-membered cycloalkyl group is optionally via a -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted;

[0020] Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocyclic alkyl groups; wherein the 3- to 14-membered heterocyclic alkyl group is optionally substituted via -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted;

[0021] Unsubstituted, monosubstituted, or polysubstituted 6- to 14-membered aryl groups; wherein the 6- to 14-membered aryl groups are optionally substituted via -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted;

[0022] Or unsubstituted, monosubstituted, or polysubstituted 5- to 14-membered heteroaryl groups; wherein the 5- to 14-membered heteroaryl groups are optionally substituted via -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted;

[0023] Furthermore, "mono- or poly-substituted" in each case independently indicates substitution by one or more substituents, wherein the one or more substituents are independently selected from fluorine, chlorine, bromine, iodine, cyano, C 1-6 Alkyl, trifluoromethyl, difluoromethyl, monofluoromethyl, -CF2Cl, -CFC12, -C 1-6 Alkylene-CF3, -C 1-6 Alkylene -CF2H, -C 1-6 Alkylene -CFH2, -C 1-6alkylene-O-CF3, -C l-6 alkylene-O-CF2H, -C 1-6 alkylene-O-CFH2, -C 1-6 alkylene-NH-C l-6 alkylene-CF3, -C 1-6 alkylene-N(C 1-6 alkyl)-C 1-6 alkylene-CF3, -C(=O)-C 1-6 alkyl, -C 1-6 alkylene-C(=O)-C 1-6 alkyl, -C(=O)OH, -C l-6 alkylene-C(=O)-OH, -C(=O)-OC 1-6 alkyl, -C l-6 alkylene-C(=O)-OC 1-6 alkyl, -C(=O)O-C 1-6 alkylene-CF3, -C(=O)-NH2, -C 1-6 alkylene-C(=O)-NH2, -C(=O)-NH(C 1-6 alkyl), -C l-6 alkylene-C(=O)-NH(C 1-6 alkyl), -C(=O)-N(C 1-6 alkyl)2, -C l-6 alkylene-C(=O)-N(C 1-6 alkyl)2, -C(=O)-NH(OH), -C l-6 alkylene-C(=O)-NH(OH), -OH, -C l-6 alkylene-OH, =O, -OCF3, -OCF2H, -OCFH2, -OCF2Cl, -OCFC12, -O-C 1-6 alkyl, -C 1-6 alkylene-O-C 1-6 alkyl, -O-C 1-6 alkylene-O-C 1-6 alkyl, -O-C 1-6 alkylene-NH2, -O-C 1-6 alkylene-NH-C l-6 alkyl, -O-C 1-6 alkylene-N(C l-6 alkyl)2, -O-C(=O)-C 1-6 alkyl, -C l-6 alkylene-O-C(=O)-C 1-6 alkyl, -O-C(=O)-O-C 1-6 alkyl, -C l-6 alkylene-O-C(=O)-O-C1-6 alkyl, -0-C(=0)-NH(C 1-6 alkyl), -C l-6 alkylene-0-C(=0)-NH(C 1-6 alkyl), -0-C(=0)-N(C 1-6 alkyl)2, -C l-6 alkylene-0-C(=0)-N(C 1-6 alkyl)2, -0-S(=0)2-NH2, -C 1-6 alkylene-0-S(=0)2-NH(C 1-6 alkyl), -C l-6 alkylene-0-S(=0)2-NH(C 1-6 alkyl), -0-S(=0)2-N(C l-6 alkyl)2, -C l-6 alkylene-0-S(=0)2-N(C l-6 alkyl)2, -NH2, -NO, -N02, -C l-6 alkylene-NH2, -NH(C l-6 alkyl), -N(3- to 14-membered cycloalkyl)(C l-6 alkyl), -N(C l-6 alkyl)-C l-6 alkylene-OH, -N(H)-C 1-6 alkylene-OH, -C l-6 alkylene-NH(C l-6 alkyl), -N(C l-6 alkyl)2, -C l-6 alkylene-N(C l-6 alkyl)2, -NH-C(=0)-C 1-6 alkyl, -C l-6 alkylene-NH-C(=0)-C 1-6 alkyl, -NH-C(=0)-0-C 1-6 alkyl, -C l-6 alkylene-NH-C(=0)-0-C 1-6 alkyl, -NHC(=0)-NH2, -C l-6 alkylene-NH-C(=0)-NH2, -NH-C(=0)-NH(C 1-6 alkyl), -C l-6 alkylene-NH-C(=0)-NH(C l-6 alkyl), -NH-C(=0)-N(C 1-6 alkyl)2, -C l-6 alkylene-NH-C(=0)-N(C 1-6 alkyl)2, -N(Cl-6 alkyl)-C(=O)-C l-6 alkyl, -C l-6 alkylene-N(C l-6 alkyl)-C(=O)-C 1-6 alkyl, -N(C l-6 alkyl)-C(=O)-O-C 1-6 alkyl, -C l-6 alkylene-N(C l-6 alkyl)-C(=O)-O-C 1-6 alkyl, -N(C l-6 alkyl)-C(=O)-NH2, -C 1-6 alkylene-N(C 1-6 alkyl)-C(=O)-NH2, -N(C 1-6 alkyl)-C(=O)-NH(C 1-6 alkyl), -C 1-6 alkylene-N(C 1-6 alkyl)-C(=O)-NH(C 1-6 alkyl), -N(C 1-6 alkyl)-C(=O)-N(C 1-6 alkyl)2, -C 1-6 alkylene-N(C 1-6 alkyl)-C(=O)-N(C 1-6 alkyl)2, -NH-S(=O)2OH, -C 1-6 alkylene-NH-S(=O)2OH, -NH-S(=O)2-C 1-6 alkyl, -C 1-6 alkylene-NH-S(=O)2-C 1-6 alkyl, -NH-S(=O)2-O-C 1-6 alkyl, -C 1-6 alkylene-NH-S(=O)-O-C 1-6 alkyl, -NH-S(=O)2-NH2, -C 1-6 alkylene-NH-S(=O)2-NH2, -NH-S(=O)2-NH(C 1-6 alkyl), -C 1-6 alkylene-NH-S(=O)2-NH(C 1-6 alkyl), -NH-S(=O)2N(C 1-6 alkyl)2, -C 1-6 alkylene-NH-S(=O)2N(C 1-6 alkyl)2, -N(C 1-6 alkyl)-S(=O)2-OH, -C 1-6 alkylene-N(C 1-6alkyl)-S(=0)2-C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -C 1-6 alkyl, -Calkyl, C 1-6 alkylene-S(=0)2-N(C 1-6 alkyl)2, 3- to 14-membered cycloalkyl, 1-6 alkylene-(3- to 14-membered cycloalkyl), 3- to 14-membered heterocycloalkyl, 1-6 alkylene-(3- to 14-membered heterocycloalkyl), -phenyl, -C 1-6 alkylene-phenyl, 5- to 14-membered heteroaryl, -C 1-6 alkylene-(5- to 14-membered heteroaryl), -0-(3- to 14-membered cycloalkyl), -0-(3- to 14-membered heterocycloalkyl), -0-phenyl, -0-(5- to 14-membered heteroaryl), -C(=0)-(3- to 14-membered cycloalkyl), -C(=0)-(3- to 14-membered heterocycloalkyl), -C(=0)-phenyl, -C(=0)-(5- to 14-membered heteroaryl), -S(=0)2-(3- to 14-membered cycloalkyl), -S(=0)2-(3- to 14-membered heterocycloalkyl), -S(=0)2-phenyl, or -S(=0)2-(5- to 14-membered heteroaryl).

[0024] Preferably, each of W1, W2, W3, and W4is independently selected from -C(R9)- or -N-, and 1 to 2 of W1, W2, W3, and W4are -N-;

[0025] L is selected from -C(R 10 R 11 )-, -N(R 12 )-, or -O-;

[0026] R1, R2, R3, R4, R5, R6, R7, and R9are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, hydroxyl, amino, C 1-8 alkyl, C 3-8 cycloalkyl, C 1-8 alkyl, C 3-8 alkyl, C 5-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 1-8 aryl, or 5- to 8-membered heteroaryl;

[0027] wherein the above groups are optionally further substituted by one or more substituents selected from hydrogen, deuterium, halogen, cyano, nitro, azido, hydroxyl, amino, C 3-8 alkyl, C 1-8 cycloalkyl, halogen-substituted C 1-8 alkyl, C 3-8 alkyl, C 5-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 10 aryl, or 5- to 8-membered heteroaryl;

[0028] R10 and R 11 Each is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 cycloalkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy groups, 3- to 8-membered heterocyclic groups, C 5-8 aryl or 5 to 8-membered heteroaryl, or R 10 R 11 Together with the carbon atom directly attached to it, it forms a carbonyl group, C 3-8 Cycloalkyl or 3 to 8-membered heterocyclic groups,

[0029] The aforementioned groups may optionally be further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-8 Alkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy groups, 3- to 8-membered heterocyclic groups, C 5-8 Substituted by aryl or 5 to 8-membered heteroaryl groups;

[0030] R8 and R 12 Each is independently selected from hydrogen, deuterium, hydroxyl, amino, C 1-8 Alkyl, C 3-8 cycloalkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy groups, 3- to 8-membered heterocyclic groups, C 5-8 Aryl or 5- to 8-membered heteroaryl,

[0031] The aforementioned groups may optionally be further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-8 Alkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy groups, 3- to 8-membered heterocyclic groups, C 5-8 Substituted by aryl or 5 to 8-membered heteroaryl groups;

[0032] R 13 Selected from hydroxyl or R Y1 ;

[0033] R 14 Selected from R Y2 or -S(O)2R Y3 ;

[0034] Or R 13 R14 together with the nitrogen atom directly attached thereto, form a saturated or unsaturated 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, or S, wherein said 3- to 8-membered heterocyclic ring is optionally further substituted with one or more substituents selected from hydrogen, deuterium, halogen, cyano, nitro, azido, hydroxy, amino, C 1-8 alkyl, C 3-8 cycloalkyl, halogen-substituted C 1-8 alkyl, C 1-8 alkyloxy, C 3-8 cycloalkyloxy, 3- to 8-membered heterocyclyl, C 5-8 aryl, or 5- to 8-membered heteroaryl.

[0035] Preferably, L is selected from -C(R 10 R 11 )-, -N(R 12 )-, or -O-;

[0036] R1is selected from hydrogen, deuterium, fluorine, chlorine, cyano, nitro, azido, hydroxy, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxetanyl, azolidinyl, azepanyl, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideuteromethyl, difluoromethyl, dideuteromethyl, dimethylamino, or aminomethyl;

[0037] R2, R3, R4, R5, R6, R7, and R9are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, nitro, azido, hydroxy, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxetanyl, azolidinyl, piperazinyl, morpholinyl, azepanyl, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideuteromethyl, difluoromethyl, dideuteromethyl, dimethylamino, or aminomethyl,

[0038] optionally further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, nitro, azido, hydroxy, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxetanyl, azolidinyl, piperazinyl, morpholinyl, azepanyl, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideuteromethyl, difluoromethyl, dideuteromethyl, dimethylamino, or aminomethyl;

[0039] R 10 , R 11 each independently is selected from hydrogen, deuterium, fluorine, chlorine, hydroxyl, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, trifluoromethyl, trideuteromethyl, difluoromethyl, dideuteromethyl, or R 10 , R 11 and the carbon atom directly attached thereto together form a carbonyl, cyclopropyl, cyclobutyl, cyclopentyl or oxetanyl;

[0040] R8, R 12 each independently is selected from hydrogen, deuterium, hydroxyl, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, trideuteromethoxy, methoxyethyl, ethoxyethyl, trifluoromethyl, trideuteromethyl, difluoromethyl or dideuteromethyl;

[0041] R 13 is selected from hydroxyl or R Y1 ;

[0042] R 14 is selected from R Y2 or -S(O)2R Y3 ;

[0043] or R 13 , R 14 and the nitrogen atom directly attached thereto together form a saturated or unsaturated 3- to 8-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O or S, wherein said 3- to 8-membered heterocyclic ring is optionally further substituted by one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, cyano, nitro, hydroxyl, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxetanyl, azolidinyl, piperazinyl, morpholinyl, azinanyl, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideuteromethyl, difluoromethyl, dideuteromethyl, dimethylamino or aminomethyl.

[0044] Preferably,

[0045] R1is selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, ethoxy, trifluoromethyl, trideuteromethyl, difluoromethyl or dideuteromethyl;

[0046] R2, R3, R4, R5, R6, R7, and R9are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, nitro, hydroxyl, amino, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, oxetanyl, azetidinyl, piperazinyl, morpholinyl, azocanyl, methoxy, trifluoromethoxy, difluoromethoxy, trideuteromethoxy, dideuteromethoxy, trifluoromethyl, trideuteromethyl, difluoromethyl, di deuteromethyl, or dimethylamino;

[0047] R 10 , R 11 are each independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, trideuteromethoxy, trifluoromethyl, trideuteromethyl, or R 10 , R 11 and the carbon atom directly attached thereto together form a carbonyl, cyclopropyl, cyclobutyl, or oxetanyl;

[0048] R8, R 12 are each independently selected from hydrogen, deuterium, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, trifluoromethyl, or trideuteromethyl.

[0049] Preferably, R 13 is selected from R Y1 ;

[0050] R 14 is selected from R Y2 or -S(O)2R Y3 ;

[0051] or R 13 , R 14 and the nitrogen atom directly attached thereto together form a saturated or unsaturated 3- to 6-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, or S, wherein said 3- to 6-membered heterocycle is optionally further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxyl, amino, methyl, ethyl, isopropyl, cyclopropyl, azocanyl, methoxy, trifluoromethoxy, trideuteromethoxy, hydroxymethyl, trifluoromethyl, trideuteromethyl, dimethylamino, or aminomethyl.

[0052] Preferably, W4is a bond, W1, W2, W3together with the two carbon atoms to which they are attached form a thiazole ring.

[0053] Preferably, said X is selected from the following structures:

[0054]

[0055] Preferably, said compound is selected from:

[0056] Compound S1, as shown above;

[0057]

[0058] Compound S2, as shown above;

[0059]

[0060] Compound S3, as shown above;

[0061]

[0062] Compound S4, as shown above;

[0063]

[0064] Compound S5, as shown above;

[0065]

[0066] Compound S6, as shown above;

[0067]

[0068] Compound S7, as shown above;

[0069]

[0070] Compound S8, as shown above;

[0071]

[0072] Compound S9, as shown above;

[0073]

[0074] Compound S10, as shown above;

[0075]

[0076] Compound S11, as shown above;

[0077]

[0078] Compound S12, as shown above;

[0079]

[0080] Compound S13, as shown above;

[0081]

[0082] Compound S14, as shown above;

[0083]

[0084] Compound S15, as shown above;

[0085]

[0086] Compound S16, as shown above;

[0087]

[0088] Compound S17, as shown above;

[0089]

[0090] Compound S18, as shown above;

[0091]

[0092] Compound S19, as shown above;

[0093]

[0094] Compound S20, as shown above;

[0095]

[0096] Compound S21, as shown above;

[0097]

[0098] Compound S22, as shown above;

[0099]

[0100] Compound S23, as shown above;

[0101]

[0102] Compound S24, as shown above;

[0103]

[0104] Compound S25, as shown above;

[0105]

[0106] Compound S26, as shown above;

[0107]

[0108] Compound S27, as shown above;

[0109]

[0110] Compound S28, as shown above;

[0111]

[0112] Compound S29, as shown above;

[0113]

[0114] Compound S30, as shown above;

[0115]

[0116] Compound S31, as shown above;

[0117]

[0118] Compound S32, as shown above;

[0119]

[0120] Compound S33, as shown above;

[0121]

[0122] Compound S34, as shown above;

[0123]

[0124] Compound S35, as shown above;

[0125]

[0126] Compound S36, as shown above;

[0127]

[0128] Compound S37, as shown above;

[0129]

[0130] Compound S38, as shown above.

[0131] The present application provides a kind of compound shown in formula I, or its pharmaceutically acceptable salt, deuterium compound, solvate, racemic mixture, enantiomer, diastereoisomer and tautomer, in the application of treating pain drug.

[0132] The application provides application of a compound shown in a formula I, or pharmaceutically acceptable salts, deuterium compounds, solvates, racemic mixtures, enantiomers, diastereoisomers and tautomers thereof in preparation of a medicine for treating neuropathic pain.

[0133] The application provides application of a compound shown in a formula I, or pharmaceutically acceptable salts, deuterium compounds, solvates, racemic mixtures, enantiomers, diastereoisomers and tautomers thereof in preparation of a medicine for treating migraine.

[0134] The application provides a pharmaceutical composition, comprising a compound shown in a formula I or pharmaceutically acceptable salts, deuterium compounds, solvates, racemic mixtures, enantiomers, diastereoisomers, tautomers and pharmaceutically acceptable carriers.

[0135] Beneficial effects:

[0136] The application discloses a kind of benzofuran derivative compounds, the characteristics of this kind of compound are with TRPM3 antagonistic activity, can be used to prepare the drug for treating neuropathic pain or migraine. DETAILED DESCRIPTION

[0137] The technical solutions in the embodiments of the present application will be described clearly and completely below with reference to the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all. Based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without creative labor fall within the scope of the present application.

[0138] "Substituted" means that one or more hydrogen atoms in a group are independently replaced by a corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions, which can be determined (by experiment or theory) by those skilled in the art without much effort. For example, free amino or hydroxyl groups combined with carbon atoms with unsaturated bonds (such as alkenes) can be unstable.

[0139] Example 1: synthesis of compound S1

[0140]

[0141] Synthesis of intermediate B1 in step 1

[0142] NMP (10 ml), dimethyl glycine (100 mg, 0.9 mmol, 0.3 eq), cesium carbonate (1.98 g, 6.0 mmol, 2.0 eq), a2 (940 mg. 4.5 mmol, 1.5 eq), A1 (660 mg, 3.0 mmol, 1.0 eq), CuI (600 mg, 3.15, 1.05 eq), nitrogen replacement 3 times, then heated to 120 °C overnight, TLC (PE / EA = 10 / 1), the raw material disappeared, the reaction was complete, 20 ml water was added, washed with saturated NaCl, dried with anhydrous Na2S04, filtered, rotary evaporated, the crude product was column chromatographed (petroleum ether: ethyl acetate = 10:1), and white solid B1 was obtained. 450 mg, yield 43.22% ESI-MS: 348.3 [M+H]+

[0143] Synthesis of intermediate C1 in step 2

[0144] B1 (450 mg, 1.29 mmol, 1.0 eq), NaOH (460 mg, 11.6 mmol, 9.0 eq), 5 ml of methanol, 2 ml of water were added, and refluxed overnight. After completion, the PH was adjusted to 5 to 6, and C1 was precipitated and filtered. 400 mg, yield 97.20% ESI-MS: 320.6 [M+H]+

[0145] Step 3

[0146] C1 (400 mg, 1.25 mmol, 1.0 eq), D1 (200 mg, 1.42 mmol, 1.15 eq), TEA (400 mg, 3.96 mmol, 3.0 eq), HATU (720 mg, 1.89 mmol, 1.5 eq) were added in turn into dichloromethane 5 ml, stirred at room temperature, and monitored by TLC (DCM / MeOH = 10 / 1) until the raw material disappeared. The reaction was complete, 60 ml of water was added to precipitate the crude product, 10 ml of EA was added, and the white solid S1 was obtained by hot slurry. 550 mg, yield 69.13% ESI-MS: 406.3 [M+H]+

[0147] 1H NMR (400 MHz, DMSO-d6) δ 8.99 (d, J = 3.4 Hz, 1H), 8.66 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.75 - 7.59 (m, 4H), 7.59 - 7.55 (m, 1H), 7.48 (s, 1H), 7.25 - 7.01 (m, 2H), 6.90 (d, J = 7.7 Hz, 1H), 5.15 (d, J = 135.3 Hz, 1H), 4.45 (q, J = 5.0 Hz, 1H), 3.71 (d, J = 4.9 Hz, 2H), 2.70 (s, 3H).

[0148] Example 2: Synthesis of compound S2

[0149]

[0150] Synthesis of intermediate B2 in step 1

[0151] Pyridine (5 ml), cesium carbonate (148 mg, 2.72 mmol, 2.0 eq), a2 (426 mg, 2.04 mmol, 1.5 eq), A1 (300 mg, 1.36 mmol, 1 eq), CuI (47.5 mg, 1.49 mmol, 1.1 eq), nitrogen replacement for 3 times, then heated to 120 °C overnight, TLC (PE / EA = 5 / 1), the raw material disappeared, the reaction was complete, 20 ml water was added to wash, saturated NaCl was washed, anhydrous Na2SO4 was dried, filtered, rotary evaporated, the crude product was column chromatographed on silica gel (petroleum ether: ethyl acetate = 5:1), and white solid B2 300 mg was obtained in a yield of 46.32%, ESI-MS: 348.3 [M+H]+;

[0152] Synthesis of intermediate C2 in step 2

[0153] B1 (300 mg, 0.86 mmol, 1 eq), NaOH (138 mg, 3.45 mmol, 4 eq) were added into methanol 5 ml, water 2 ml, and refluxed overnight. After the reaction was completed, the PH was adjusted to 5 to 6, and C2 300 mg was precipitated and filtered in a yield of 97.20%, ESI-MS: 320.6 [M+H]+;

[0154] Step 3

[0155] C1 (300 mg, 094 mmol, 1 eq), D1 (172 mg, 1.22 mmol, 1.3 eq), DIPEA (606 mg, 4.7 mmol, 5 eq), HATU (535.8 mg, 1.44 mmol, 1, 5 eq) were sequentially added into DMF 4.5 ml, and stirred at room temperature. TLC (DCM / MeOH = 10 / 1) was used for monitoring until the raw material disappeared. After the reaction was completed, 10 ml of water was added to precipitate the crude product, which was filtered and dried to obtain white solid S2 280 mg, ESI-MS: 406.3 [M+H]+

[0156] 1H NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 1.0 Hz, 1H), 8.57 (d, J = 5.9 Hz, 1H), 8.05 (dd, J = 5.9, 1.0 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.76 - 7.56 (m, 2H), 7.53 (d, J = 2.5 Hz, 1H), 7.18 - 7.06 (m, 2H), 4.43 (t, J = 5.2 Hz, 1H), 3.70 (d, J = 5.2 Hz, 2H), 3.58 (s, 4H), 2.69 (s, 3H).

[0157] Example 3: Synthesis of compound S3

[0158]

[0159] Synthesis of intermediate B3 in Step 1

[0160] Pyridine 10 ml, A1 (220 mg, 1.0 mmol, 1.0 eq), a3 (330 mg, 1.5 mmol, 1.5 eq), CuI (210 mg, 1.1 mmol, 1.1 eq), cesium carbonate (650 mg, 2.0 mmol, 2.0 eq) were added successively, replaced with nitrogen for 3 times, then heated to 120°C overnight, TLC (PE / EA = 5 / 1) monitoring until the raw material basically disappeared. After the reaction was completed, it was concentrated to dryness, and the next step was directly treated without treatment

[0161] Synthesis of intermediate C3 in Step 2

[0162] Methanol 10 ml, B3 crude product (theoretically), NaOH (160 mg, 4.0 mmol, 4.0 eq), water 1 ml were added in a 50 ml reaction bottle, and reacted at 50°C overnight. TLC (PE / EA = 5 / 1, DCM / MeOH = 40 / 1) monitoring until the raw material disappeared, the PH was adjusted to 5 to 6, and the solid was precipitated and filtered to obtain C3 260 mg; ESI-MS: 334.6 [M+H]+

[0163] Step 3

[0164] DMF 5 ml, C3 (260 mg, 0.78 mmol, 1.0 eq), D2 (155

[0165] mg, 1.1 mmol, 1.3 eq), DIPEA (560 mg, 4.3 mmol, 5.0 eq), HATU (500 mg 1.29 mmol, 1.5 eq) at room temperature for half an hour, TLC (DCM / MeOH = 40 / 1) monitoring reaction complete, slowly drop 50 ml of water, solid precipitate filtration, collect the filter cake, filter cake with a large amount of water, collect the collected S3130 mg yield 39.73%; ESI-MS: 418.42 [M+H]+

[0166] Example 4: Synthesis of compound S4

[0167]

[0168] Synthesis of intermediate B4 in step 1

[0169] A1 (160 mg, 0.725 mmol, 1.0 eq) was added to a 25 ml single-necked flask, then 16.5 ml of pyridine was added, and then a4 (250 mg, 1.03 mmol, 1.5 eq), Cs2CO3 (488.4 mg, 1.5 mmol, 2.0 eq), CuI (156.27 mg, 0.82 mmol, 1.1 eq) were added in turn, then stirred uniformly, and then warmed to 130°C for overnight reaction. The reaction liquid turned black, TLC and LCMS detection (tlc = PE:EA = 5:1), LCMS correct column purification (PE:EA = 100:~5:1) to get 220 mg of white solid B3 with a yield of 40.8%; ESI-MS: 362.3 [M+H]+

[0170] Synthesis of intermediate C4 in step 2

[0171] B4 (220 mg, 0.61 mmol, 1 eq) was added to 2 ml of methanol, stirred uniformly, then NaOH (98 mg, 2.45 mmol, 4 eq) was added, TLC (DCM:MeOH = 10;1) after the reaction was complete, the solvent was dried and column purified (DCM:MeOH = 100~5:1), to get 90 mg of white solid C4 with a yield of 45%; ESI-MS: 334.6 [M+H]+;

[0172] Step 3

[0173] D1 (50 mg, 0.36 mmol, 1.3 eq) was stirred in 4.5 ml DMF, D1 was not dissolved, DIPEA (174 mg, 0.15 mmol, 5 eq) was added to the reaction, stirred evenly, the reaction solution was dissolved, then HATU (154 mg, 0.41 mmol, 1.5 eq) was added to the reaction, the reaction solution was dissolved, and the reaction was carried out at room temperature for 30 minutes. TLC and LCMS monitoring, TLC (DCM:MeOH = 10:1) LCMS correct reaction was complete, 10 volumes of water (45 ml) was added, a large amount of solid was precipitated, then filtered, the solid was the product, and the solid was dried. ESI-MS: 420.4 [M+H]+

[0174] 1H NMR (400 MHz, DMSO-d6) δ 8.49 (d, J = 8.6 Hz, 1H), 7.74 - 7.59 (m, 3H), 7.56 - 7.42 (m, 2H), 7.09 (dd, J = 8.9, 2.5 Hz, 1H), 6.84 (dd, J = 7.6, 1.1 Hz, 1H), 4.44 (t, J = 5.2 Hz, 1H), 3.70 (d, J = 5.2 Hz, 2H), 3.59 (s, 6H), 2.69 (s, 6H).

[0175] Example 5: Synthesis of compound S5

[0176]

[0177] Synthesis of intermediate B5 in step 1

[0178] A1 (300 mg, 1.36 mmol, 1 eq) was added to a single-necked flask, then pyridine (5 ml) was added, stirred evenly, a5 (426 mg, 2.04 mmol, 1.5 eq), Cs2CO3 (148 mg, 2.72 mmol, 2.0 eq), CuI

[0179] (47.5 mg, 1.49 mmol, 1.1 eq) were added in turn, then stirred evenly, and the temperature was raised to 130°C and reacted overnight. TLC and LCMS detection (TLC = PE:EA = 5:1), column purification (PE:EA = 20:1--5:1), white solid B5 (300 mg containing solvent) was obtained

[0180] Synthesis of intermediate C5 in step 2

[0181] B5 (300 mg, 0.86 mmol, 1 eq) was added to a 10 ml single-necked flask, then 5 ml of methanol was added, after stirring, NaOH (138 mg, 3.45 mmol, 4 eq) was added, TLC monitoring, TLC (DCM:MeOH = 10; 1) was complete, then EA was diluted, 1M hydrochloric acid was added to adjust PH = 5, precipitation was obtained, and the solid was dried to obtain white solid C5 (300 mg of crude product).

[0182] Step 3

[0183] C5 (300 mg, 0.94 mmol, 1 eq) was added to DMF (4.5 ml) and stirred uniformly, D1 (172 mg, 1.22 mmol, 1.3 eq) was added to the reaction, the reaction was not dissolved, and after stirring uniformly, DIPEA (606 mg, 4.7 mmol, 5 eq) was added to the reaction, then HATU (535.8 mg, 1.44 mmol, 1.5 eq) was added, the reaction solution was dissolved, and the reaction was carried out at room temperature for 30 minutes, TLC and LCMS monitoring, TLC (DCM:MeOH = 10:1) LCMS was correct, after the reaction was complete, 10 volumes of water was added, a large amount of solid was precipitated, then filtered, the solid was the product, and the solid was dried to obtain 160 mg of S5; ESI-MS: 406.3 [M+H]+

[0184] 1H NMR (400 MHz, DMSO-d6) δ 8.88 (dd, J = 4.2, 1.7 Hz, 1H), 8.43 (dd, J = 8.4, 1.7 Hz, 1H), 7.77 (dd, J = 8.2, 1.3 Hz, 1H), 7.64-7.53 (m, 3H), 7.42 (d, J = 2.5 Hz, 1H), 7.21 (dd, J = 7.6, 1.2 Hz, 1H), 6.98 (dd, J = 8.9, 2.5 Hz, 1H), 4.42 (t, J = 5.1 Hz, 1H), 3.69 (d, J = 5.2 Hz, 2H), 3.59 (s, 4H), 2.68 (s, 3H).

[0185] Example 6: Synthesis of compound S6

[0186]

[0187] According to the synthesis method of S1 to S5, compound S6 was synthesized by using the corresponding raw materials.

[0188] ESI-MS: 412.3 [M+H]+

[0189] 1H NMR (400 MHz, DMSO-d6) δ 9.34 (s, 1H), 7.81 (d, J = 8 Hz, 1H), 7.59 (d, J = 8 Hz, 1H), 7.49 (m, 2H), 7.07 (d, J = 8 Hz, 1H), 6.88 (d, J = 8 Hz, 1H), 4.38 (t, J = 5 Hz, 1H), 3.64 (m, 2H), 3.51 (m, 4H), 2.63 (s, 3H).

[0190] Example 7: Detection of TRPM3 antagonistic activity of compounds

[0191] 1. Cell culture and transfection

[0192] Human embryonic kidney 293T (HEK 293T) cells for transient transfection were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% double antibiotics. HEK 293T cells were transiently transfected with human TRPM3 in pcDNA3.4 vector. Transfection efficiency was observed 24 h after transfection and plated for seeding. Functional studies were performed 72 h after transfection.

[0193] 2. Intracellular Ca2+ measurement 2+ Measurement

[0194] Fluorescence assay of cells was performed in 96-well plates. Fluorescent indicator Fluo-4 / AM and different concentrations of TRPM3 inhibitors were added to HEK 293T cells expressing TRPM3 and incubated at 37 °C for 1 h. Then, the 96-well plates were placed in a multifunctional enzyme label instrument Flex Station 3, and 494 nm and 516 nm were applied as excitation and emission wavelengths, respectively, to detect the fluorescence intensity before and after the addition of TRPM3 agonist PregS. To ensure the accuracy of the test results, the method of subtracting background fluorescence signal was used to calculate the fluorescence change rate (ΔF / F0) of each well, so as to more accurately evaluate the effect of different concentrations of TRPM3 inhibitors on intracellular Ca2+ flux and TRPM3 channel activity. 2+ Measurement

[0195] The results are shown in the table, and compounds S1-S5 have TRPM3 antagonistic activity. The TRPM3 IC50 value ranges represented by activity ranges A, B and C are as follows: “A” indicates IC50 < 1 μM; “B” indicates 1 μM ≤ IC50 ≤ 20 μM; and “C” indicates IC50 > 20 μM.

[0196]

[0197] It will be apparent to those skilled in the art that the application is not limited to the details of the above-exemplified embodiments and that the present application can be implemented in other particular forms without departing from the spirit or essential characteristics of the present application. The embodiments should therefore be considered in all respects as illustrative and not restrictive, the scope of the application being indicated by the appended claims rather than by the above description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. No reference herein to any prior patents or applications shall be taken as an admission that the application is not entitled to antedate such prior patents or applications by virtue of prior application. Any reference to the use of a term in the singular herein shall be taken as an acknowledgment of the existence of the term in the plural and vice versa.

Claims

1. A class of compounds of formula I or pharmaceutically acceptable salts, deuterated compounds, solvates, racemic mixtures, enantiomers, diastereomers, and tautomers thereof, characterized in that, Among them, W1, W2 and W3 are each independently selected from -C(R9)-, -N-, -N(R8)-, -O- or -S-; W4 is selected from -C(R9)-, -N- or W4 is the key; L is selected from -C(R) 10 R 11 )-、-N(R 12 -, -S-, or -O-; R1, R2, R3, R4, R5, R6, R7, and R9 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, and C. 1-14 Alkyl, C 3-14 cycloalkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 aryl or 5 to 14-membered heteroaryl, wherein the above groups are optionally further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted with aryl or 5 to 14 heteroaryl groups; X is selected from -NR 13 R 14 ; R 10 and R 11 Each is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 cycloalkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 aryl or 5 to 14-membered heteroaryl, or R 10 R 11 Together with the carbon atom directly attached to it, it forms a carbonyl group, C 3-14 Cycloalkyl or 3 to 14-membered heterocyclic groups, wherein the above groups are optionally further surrounded by one or more groups selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted with aryl or 5 to 14 heteroaryl groups; R8 and R 12 Each is independently selected from hydrogen, deuterium, hydroxyl, amino, C 1-14 Alkyl, C 3-14 cycloalkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 aryl or 5 to 14-membered heteroaryl, wherein the above groups are optionally further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted with aryl or 5 to 14 heteroaryl groups; R 13 Selected from hydroxyl or R Y1 ; R 14 Selected from R Y2 or -S(O)2R Y3 Or R 13 R 14 Together with the nitrogen atom directly bonded thereto, it forms a saturated or unsaturated 3- to 14-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, or S, wherein the 3- to 14-membered heterocycle is optionally further bounded by one or more atoms selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-14 Alkyl, C 3-14 Cycloalkyl, halogenated C 1-14 Alkyl, C 1-14 Alkyloxy, C 3-14 Cycloalkyloxy, 3 to 14-membered heterocyclic groups, C 5-14 Substituted with aryl or 5 to 14 heteroaryl groups; R Y1 R Y2 R Y3 Independently selected from each other in each case: hydrogen; Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted C 1-6 alkyl; Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted C 1-6 Heteroalkyl; Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered cycloalkyl groups; wherein the 3- to 14-membered cycloalkyl group is optionally via a -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted; Saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3- to 14-membered heterocyclic alkyl groups; wherein the 3- to 14-membered heterocyclic alkyl group is optionally substituted via -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted; Unsubstituted, monosubstituted, or polysubstituted 6- to 14-membered aryl groups; wherein the 6- to 14-membered aryl groups are optionally substituted via -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted; Or unsubstituted, monosubstituted, or polysubstituted 5- to 14-membered heteroaryl groups; wherein the 5- to 14-membered heteroaryl groups are optionally substituted via -C 1-6 alkylene- or -C 1-6 Heteroalkyl-linked, wherein the alkylene or heteroalkylene group is, in each case, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted; Furthermore, "mono- or poly-substituted" in each case independently indicates substitution by one or more substituents, wherein the one or more substituents are independently selected from fluorine, chlorine, bromine, iodine, cyano, C 1-6 Alkyl, trifluoromethyl, difluoromethyl, monofluoromethyl, -CF2Cl, -CFC12, -C 1-6 Alkylene-CF3, -C 1-6 Alkylene -CF2H, -C 1-6 Alkylene -CFH2, -C 1-6 Alkylene -O-CF3, -C l-6 Alkylene -O-CF2H, -C 1-6 Alkylene -O-CFH2, -C 1-6 Alkylene-NH-C l-6 Alkylene-CF3, -C 1-6 Alkylene-N(C) 1-6 alkyl)-C 1-6 Alkylene-CF3, -C(=O)-C 1-6 Alkyl, -C 1-6 Alkylene-C(=O)-C 1-6 Alkyl, -C(=O)OH, -C l-6 Alkylene -C(=O)-OH, -C(=O)-OC 1-6 Alkyl, -C l-6 Alkylene-C(=O)-OC 1-6 Alkyl group, -C(=O)OC 1-6 Alkylene -CF3, -C(=O)-NH2, -C 1-6 Alkylene -C(=O)-NH2, -C(=O)-NH(C 1-6 Alkyl), -C l-6 Alkylene-C(=O)-NH(C) 1-6 Alkyl), -C(=O)-N(C 1-6 Alkyl)2, -C l-6 Alkylene-C(=O)-N(C) 1-6 Alkyl)2, -C(=O)-NH(OH), -C l-6 Alkylene -C(=O)-NH(OH), -OH, -C l-6 Alkylenes -OH, =O, -OCF3, -OCF2H, -OCFH2, -OCF2Cl, -OCFC12, -OC 1-6 Alkyl, -C 1-6 Alkylene-OC 1-6 Alkyl, -OC 1-6 Alkylene-OC 1-6 Alkyl, -OC 1-6 Alkylene -NH2, -OC 1-6 Alkylene-NH-C l-6 Alkyl, -OC 1-6 Alkylene-N(C) l-6 Alkyl)2、-OC(=O)-C 1-6 Alkyl, -C l-6 Alkylene-OC(=O)-C 1-6 Alkyl group, -OC (=O)-OC 1-6 Alkyl, -C l-6 Alkylene-OC(=O)-OC 1-6 Alkyl group, -OC(=O)-NH(C) 1-6 Alkyl), -C l-6 Alkylene-OC(=O)-NH(C) 1-6 Alkyl), -OC(=O)-N(C) 1-6 Alkyl)2, -C l-6 Alkylene-OC(=O)-N(C) 1-6 Alkyl)2, -OS(=O)2-NH2, -C 1-6 Alkylenes -OS(=O)2-NH2, -OS(=O)2-NH(C 1-6 Alkyl), -C l-6 Alkylene-OS(=O)2-NH(C) 1-6 Alkyl), -OS(=O)2-N(C l-6 Alkyl)2, -C l-6 Alkylene-OS(=O)2-N(C) l-6 Alkyl group 2, -NH2, -NO, -NO2, -C l-6 Alkylene -NH2, -NH(C l-6 Alkyl), -N (3 to 14 membered cycloalkyl) (C l-6 alkyl), -N(C) l-6 alkyl)-C l-6 Alkylene -OH, -N(H)-C 1-6 alkylene -OH, -C l-6 Alkylene-NH(C) l-6 alkyl), -N(C) l-6 Alkyl)2, -C l-6 Alkylene-N(C) l-6 Alkyl)2、-NH-C(=O)-C 1-6 Alkyl, -C l-6 Alkylene-NH-C(=O)-C 1-6 Alkyl, -NH-C(=O)-OC 1-6 Alkyl, -C l-6 Alkylene-NH-C(=O)-OC 1-6 Alkyl group, -NHC(=O)-NH2, -C l-6 Alkylene -NH-C(=O)-NH2, -NH-C(=O)-NH(C 1-6 Alkyl), -C l-6 Alkylene-NH-C(=O)-NH(C) l-6 Alkyl), -NH-C(=O)-N(C 1-6 Alkyl)2, -C l-6 Alkylene-NH-C(=O)-N(C) 1-6 Alkyl)2, -N(C l-6 alkyl)-C(=O)-C l-6 Alkyl, -C l-6 Alkylene-N(C) l-6 alkyl)-C(=O)-C 1-6 Alkyl, -N(C) l-6 alkyl)-C(=O)-OC 1-6 Alkyl, -C l-6 Alkylene-N(C) l-6 alkyl)-C(=O)-OC 1-6 Alkyl, -N(C) l-6 Alkyl)-C(=O)-NH2、-C 1-6 Alkylene-N(C) 1-6 Alkyl)-C(=O)-NH2、-N(C 1-6 alkyl)-C(=O)-NH(C 1-6 Alkyl), -C 1-6 Alkylene-N(C) 1-6 alkyl)-C(=O)-NH(C 1-6 alkyl), -N(C) 1-6 alkyl)-C(=O)-N(C 1-6 Alkyl)2, -C 1-6 Alkylene-N(C) 1-6 alkyl)-C(=O)-N(C 1-6 Alkyl)2, -NH-S(=O)2OH, -C 1-6 Alkylenes -NH-S(=O)2OH, -NH-S(=O)2-C 1-6 Alkyl, -C 1-6 Alkylene-NH-S(=O)2-C 1-6 Alkyl group, -NH-S(=O)2-OC 1-6 Alkyl, -C 1-6 Alkylene -NH-S(=O)-OC 1-6 Alkyl group, -NH-S(=O)2-NH2, -C 1-6 Alkylenes -NH-S(=O)2-NH2, -NH-S(=O)2-NH(C 1-6 Alkyl), -C 1-6 Alkylene-NH-S(=O)2-NH(C 1-6 Alkyl), -NH-S(=O)2N(C 1-6 Alkyl)2, -C 1-6 Alkylene-NH-S(=O)2N(C 1-6 Alkyl)2, -N(C 1-6 alkyl)-S(=O)2-OH, -C 1-6 Alkylene-N(C) 1-6 alkyl)-S(=O)2-OH, -N(C 1-6 alkyl)-S(=O)2-C 1-6 Alkyl, -C 1-6 Alkylene-N(C) 1-6 alkyl)-S(=O)2-C 1-6 Alkyl, -N(C) 1-6 alkyl)-S(=O)2-OC 1-6 Alkyl, -C 1-6 Alkylene-N(C) 1-6 alkyl)-S(=O)2-OC 1-6 Alkyl, -N(C) 1-6 Alkyl)-S(=O)2-NH2、-C 1-6 Alkylene-N(C) 1-6 alkyl)-S(=O)2-NH2、-N(C 1-6 alkyl)-S(=O)2-NH(C 1-6 Alkyl), -C 1-6 Alkylene-N(C) 1-6 alkyl)-S(=O)2-NH(C 1-6 alkyl), -N(C) 1-6 alkyl)-S(=O)2-N(C 1-6 Alkyl)2, -C 1-6 Alkylene-N(C) 1-6 alkyl)-S(=O)2-N(C 1-6 Alkyl group 2, -SH, =S, -SF5, -SCF3, -SCF2H, -SCFH2, -SC 1-6 Alkyl, -C 1-6 Alkylene-SC 1-6 Alkyl, -S(=O)-C 1-6 Alkyl, -C 1-6 Alkylene-S(=O)-C 1-6 Alkyl group, -S(=O)2-C 1-6 Alkyl, -C 1-6 Alkylene-S(=O)2-C 1-6 Alkyl, -S(=O)2-OH, -C 1-6 Alkylenes -S(=O)2-OH, -S(=O)2-OC 1-6 Alkyl, -C 1-6 Alkylene-S(=O)2-OC 1-6 Alkyl group, -S(=O)2-NH2, -C 1-6 Alkylene -S(=O)2-NH2, -S(=O)2-NH(C 1-6 Alkyl, -C 1-6 Alkylene-S(=O)2-NH(C) 1-6 Alkyl), -S(=O)2-N(C 1-6 Alkyl)2, -C 1-6 Alkylene-S(=O)2-N(C) 1-6 Alkyl) 2, 3 to 14-membered cycloalkyl, -C 1-6 Alkylene -(3- to 14-membered cycloalkyl), 3- to 14-membered heterocycloalkyl, -C 1-6 alkylene-(3 to 14-membered heterocyclic alkyl), -phenyl, -C 1-6 alkylene-phenyl, 5 to 14-membered heteroaryl, -C 1-6 Alkylene-(5 to 14-membered heteroaryl), -O-(3 to 14-membered cycloalkyl), -O-(3 to 14-membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3 to 14-membered cycloalkyl), -C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), -S(=O)2-(3 to 14-membered cycloalkyl), -S(=O)2-(3 to 14-membered heterocycloalkyl), -S(=O)2-phenyl or -S(=O)2-(5 to 14-membered heteroaryl).

2. The compound according to claim 1, or its pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer, characterized in that, in, W1, W2, W3 and W4 are each independently selected from -C(R9)- or -N-, and one or two of W1, W2, W3 and W4 are -N-; L is selected from -C(R) 10 R 11 )-、-N(R 12 - or -O-; R1, R2, R3, R4, R5, R6, R7, and R9 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, and C. 1-8 Alkyl, C 3-8 cycloalkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy, 3- to 8-membered heterocyclic groups, C 5-8 Aryl or 5- to 8-membered heteroaryl; The aforementioned groups may optionally be further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-8 Alkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy, 3- to 8-membered heterocyclic groups, C 5-8 Substituted by aryl or 5 to 8-membered heteroaryl groups; R 10 and R 11 Each is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 cycloalkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy, 3- to 8-membered heterocyclic groups, C 5-8 aryl or 5 to 8-membered heteroaryl, or R 10 R 11 Together with the carbon atom directly attached to it, it forms a carbonyl group, C 3-8 Cycloalkyl or 3 to 8-membered heterocyclic groups, The aforementioned groups may optionally be further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-8 Alkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy, 3- to 8-membered heterocyclic groups, C 5-8 Substituted by aryl or 5 to 8-membered heteroaryl groups; R8 and R 12 Each is independently selected from hydrogen, deuterium, hydroxyl, amino, C 1-8 Alkyl, C 3-8 cycloalkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy, 3- to 8-membered heterocyclic groups, C 5-8 Aryl or 5- to 8-membered heteroaryl, The aforementioned groups may optionally be further surrounded by one or more radicals selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-8 Alkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy, 3- to 8-membered heterocyclic groups, C 5-8 Substituted by aryl or 5 to 8-membered heteroaryl groups; R 13 Selected from hydroxyl or R Y1 ; R 14 Selected from R Y2 or -S(O)2R Y3 ; Or R 13 R 14 Together with the nitrogen atom directly bonded thereto, it forms a saturated or unsaturated 3- to 8-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, or S, wherein the 3- to 8-membered heterocycle is optionally further bonded by one or more atoms selected from hydrogen, deuterium, halogen, cyano, nitro, azide, hydroxyl, amino, C 1-8 Alkyl, C 3-8 Cycloalkyl, halogenated C 1-8 Alkyl, C 1-8 Alkyloxy, C 3-8 Cycloalkyloxy, 3- to 8-membered heterocyclic groups, C 5-8 Substituents of aryl or 5 to 8-membered heteroaryl groups.

3. The compound according to claim 1, or its pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer, characterized in that, L is selected from -C(R) 10 R 11 )-、-N(R 12 - or -O-; R1 is selected from hydrogen, deuterium, fluorine, chlorine, cyano, nitro, azide, hydroxyl, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxacyclobutyl, azircetin, azircetin, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuteroxy, dideuteroxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideutermethyl, difluoromethyl, dideutermethyl, dimethylamino, or aminomethyl; R2, R3, R4, R5, R6, R7, and R9 are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, nitro, azide, hydroxyl, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxacyclobutyl, azircetinyl, piperazine, morpholinyl, azircetin, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuterium methoxy, dideuterium methoxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideuterium methyl, difluoromethyl, dideuterium methyl, dimethylamino, or aminomethyl. The aforementioned groups may optionally be further substituted by one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, nitro, azide, hydroxyl, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxacyclobutyl, aziroxypentyl, piperazine, morpholino, aziroxyhexyl, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuteroxy, dideuteroxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideutermethyl, difluoromethyl, dideutermethyl, dimethylamino, or aminomethyl. R 10 R 11 Each is independently selected from hydrogen, deuterium, fluorine, chlorine, hydroxyl, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, difluoromethoxy, trideuteriummethoxy, dideuteriummethoxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, trifluoromethyl, trideuteriummethyl, difluoromethyl, dideuteriummethyl, or R 10 R 11 Together with the carbon atom directly attached to it, it forms carbonyl, cyclopropyl, cyclobutyl, cyclopentyl, or oxacyclobutyl groups; R8, R 12 Each is independently selected from hydrogen, deuterium, hydroxyl, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, trideuteriummethoxy, methoxyethyl, ethoxyethyl, trifluoromethyl, trideuteriummethyl, difluoromethyl, or dideuteriummethyl; R 13 Selected from hydroxyl or R Y1 ; R 14 Selected from R Y2 or -S(O)2R Y3 ; Or R 13 R 14 Together with the nitrogen atom directly attached thereto, it forms a saturated or unsaturated 3- to 8-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, or S, wherein the 3- to 8-membered heterocycle is optionally further substituted by one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, cyano, nitro, hydroxyl, amino, methyl, ethyl, isopropyl, allyl, ethynyl, cyclopropyl, cyclopropylmethyl, oxacyclobutyl, aziroxypentyl, piperazine, morpholino, aziroxyhexyl, phenyl, diazole, triazole, methoxy, trifluoromethoxy, difluoromethoxy, trideuteroxy, dideuteroxy, ethoxy, isopropoxy, methoxyethyl, ethoxyethyl, hydroxymethyl, hydroxyethyl, cyanomethyl, trifluoromethyl, trideutermethyl, difluoromethyl, dideutermethyl, dimethylamino, or aminomethyl.

4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, its deuterated compounds, solvates, racemic mixtures, enantiomers, diastereomers, and tautomers, characterized in that, R1 is selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, difluoromethoxy, trideuteriummethoxy, dideuteriummethoxy, ethoxy, trifluoromethyl, trideuteriummethyl, difluoromethyl, or dideuteriummethyl; R2, R3, R4, R5, R6, R7, and R9 are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, nitro, hydroxyl, amino, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, oxacyclobutyl, aziroxypentyl, piperazine, morpholinyl, aziroxyhexyl, methoxy, trifluoromethoxy, difluoromethoxy, trideuteroxy, dideuteroxy, trifluoromethyl, trideutermethyl, difluoromethyl, dideutermethyl, or dimethylamino; R 10 R 11 Each is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, methoxy, trifluoromethoxy, trideuteriummethoxy, trifluoromethyl, trideuteriummethyl, or R 10 R 11 Together with the carbon atom directly attached to it, it forms carbonyl, cyclopropyl, cyclobutyl or oxacyclobutyl groups; R8, R 12 Each is independently selected from hydrogen, deuterium, methyl, ethyl, isopropyl, cyclopropyl, cyclopropylmethyl, trifluoromethyl, or trideuterylmethyl.

5. The compound according to claim 1, or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer thereof, characterized in that, R 13 Selected from R Y1 ; R 14 Selected from R Y2 or -S(O)2R Y3 ; Or R 13 R 14 Together with the nitrogen atom directly attached thereto, it forms a saturated or unsaturated 3- to 6-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, or S, wherein the 3- to 6-membered heterocycle is optionally further substituted by one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, cyano, hydroxyl, amino, methyl, ethyl, isopropyl, cyclopropyl, azircyclohexyl, methoxy, trifluoromethoxy, trideuteroxy, hydroxymethyl, trifluoromethyl, trideutermethyl, dimethylamino, or aminomethyl.

6. The compound according to claim 1, or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer thereof, characterized in that, W4 is the bond, and W1, W2, W3 together with the two carbon atoms connected to them form a thiazole ring.

7. The compound according to claim 1, or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer thereof, characterized in that, X is selected from the following structure:

8. The compound according to claim 1, or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer thereof, characterized in that, The compound is selected from: Compound S1, as shown above; Compound S2, as shown above; Compound S3, as shown above; Compound S4, as shown above; Compound S5, as shown above; Compound S6, as shown above; Compound S7, as shown above; Compound S8, as shown above; Compound S9, as shown above; Compound S10, as shown above; Compound S11, as shown above; Compound S12, as shown above; Compound S13, as shown above; Compound S14, as shown above; Compound S15, as shown above; Compound S16, as shown above; Compound S17, as shown above; Compound S18, as shown above; Compound S19, as shown above; Compound S20, as shown above; Compound S21, as shown above; Compound S22, as shown above; Compound S23, as shown above; Compound S24, as shown above; Compound S25, as shown above; Compound S26, as shown above; Compound S27, as shown above; Compound S28, as shown above; Compound S29, as shown above; Compound S30, as shown above; Compound S31, as shown above; Compound S32, as shown above; Compound S33, as shown above; Compound S34, as shown above; Compound S35, as shown above; Compound S36, as shown above; Compound S37, as shown above; Compound S38, as shown above.

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer thereof, characterized in that, The compound is used in the preparation of drugs for treating pain.

10. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer thereof, characterized in that, The compound is used in the preparation of drugs for treating neuropathic pain.

11. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, and tautomer thereof, characterized in that, The compound is used in the preparation of drugs for treating migraines.

12. A pharmaceutical composition, characterized in that, It includes the compound of any one of claims 1 to 8 or a pharmaceutically acceptable salt, deuterated compound, solvate, racemic mixture, enantiomer, diastereomer, tautomer, and pharmaceutically acceptable carrier thereof.

Images